News | Oncology Diagnostics | January 02, 2018

Imagio Opto-Acoustic Breast Imaging System Helps Differentiate Tumor Subtypes

Prospective clinical study presented at the San Antonio Breast Cancer Symposium suggests Imagio findings may help clinicians tailor patient treatment regimens

Imagio Opto-Acoustic Breast Imaging System Helps Differentiate Tumor Subtypes

January 2, 2018 — Seno Medical Instruments Inc. (Seno Medical) recently reported data from their clinical study demonstrating that its Imagio opto-acoustic (OA) breast imaging system achieved significant differentiation among prognostic subtypes of breast cancer (PSBC). These prognostic subtypes provide important information about the genes that each patient's cancer expresses. The data were presented during a poster presentation at the San Antonio Breast Cancer Symposium, Dec. 5-9 in San Antonio, Texas.

"Confirming a diagnosis of breast cancer is just the first step in understanding the pathology of a patient's tumor," said study presenter Stephen Grobmyer, M.D., director, breast surgical oncology, Cleveland Clinic. "Determining a patient's prognostic subtype of breast cancer is essential for understanding how tumors will respond to specific therapies and selecting a treatment regimen that offers the patient the best chance of a positive outcome. The findings that OA/US [ultrasound] may differentiate among several breast cancer subtypes suggest that this novel imaging methodology could potentially provide a non-invasive alternative to biopsy without sacrificing information about the molecular pathology of the tumor. This could be an important advance for women with breast cancer."

The prospective, multi-center study was conducted at 16 centers in the United States. A total of 1,808 breast masses in 1,739 subjects assessed as BI-RADS (Breast Imaging and Reporting Data System,) category 3, 4 or 5 were imaged with OA/US, resulting in the identification of 678 malignant lesions. Eight blinded readers scored these 678 lesions based on three internal features of the tumor and two external features of the tumor boundary and surrounding tissue. An experienced central breast pathologist who was blinded to the OA/US assessment confirmed the pathologic diagnoses. Biopsy specimens were obtained and assessed for the expression of four genes that comprise the PSBC: estrogen receptor (ER), progesterone receptor (PR), HER2-neu (HER2) and Ki-67. The PSBCs are defined as follows:

  • Luminal A (LUM-A): ER/PR (+) and Ki-67 and HER2 (-). These tumors are often low grade, with slow tumor growth and are associated with the most positive prognosis;
  • Luminal B (LUM-B): ER (+), PR (+/-), Ki-67 (+) and HER2 (+/-). These tumors are also low grade but grow more quickly than LUM-A;
  • Triple-negative breast cancer (TNBC): ER/PR (-), Ki-67 (+/-) and HER2 (-). These tumors are aggressive and typically associated with poor prognosis; and
  • HER2-enriched (HER2): ER/PR (-), Ki-67 (+/-) and HER2 (+). These tumors tend to grow quickly but are responsive to anti-HER2 targeted therapies.

Tumors not meeting the definition of any of these categories were deemed unclassified.

Key findings from the study include:

  • There was a significant difference in the sum of the three internal OA/US features between LUM-A and TNBC subtypes (p = 0.0256) and borderline significance between LUM-A and LUM-B (p = 0.0831) and LUM-A and HER2 (p = 0.0707);
  • There was a significant difference in the sum of the two external OA/US features between LUM-A and TNBC subtypes (p = 0.0001) and LUM-B and TNBC subtypes (p = 0.0020) and borderline significance between LUM-A and HER2 (p = 0.0617);
  • TNBC tumors showed mainly internal findings consisting of polymorphic intensely deoxygenated vessels; and
  • LUM-A tumors showed a paucity of internal findings and abundant external findings consisting of short perpendicularly oriented tumor vessels in the boundary zone (BZ whiskers), partial BZ deoxygenated blush, and peripheral radiating deoxygenated vessels.

The Imagio OA/US breast imaging system was designed and is being studied to identify two functional hallmarks of cancer: the presence of abnormal blood vessels (tumor angiogenesis) and the relative reduction in oxygen content of blood that occurs in cancer compared to benign masses and normal tissues. The technology is the subject of a U.S. premarket approval (PMA) filing with the U.S. Food and Drug Administration (FDA) and does have European CE Mark.

For more information: www.senomedical.com

Related Content

Videos | Mammography | December 10, 2018
Stamatia Destounis, M.D., FACR, associate professor, University of Rochester School of Medicine, and attending radiol
Youth Football Changes Nerve Fibers in Brain

Statistically significant clusters (red-colored) showing group differences (Control vs. Football) in white matter strain along the primary (F1) and secondary (F2) fibers. While body of corpus callosum (BBC) showed relative shrinkage in Football group, the other clusters showed relative stretching of fibers. PCR: Posterior Corona Radiata, PLIC: Posterior Limb of Internal Capsule, SCR: Superior Corona Radiata, SLF: Superior Longitudinal Fasciculus, SCC: Splenium of Corpus Callosum. Image courtesy of Kim et al.

News | Neuro Imaging | December 07, 2018
Magnetic resonance imaging (MRI) scans show repetitive blows to the head result in brain changes among youth football...
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...
YITU Releases AI-Based Cancer Screening Solutions at RSNA 2018
News | Artificial Intelligence | December 06, 2018
Chinese artificial intelligence (AI) healthcare company YITU healthcare released two brand-new products, Intelligent...
Fujifilm Collaborates With Lunit on AI Pilot Project
News | Artificial Intelligence | December 05, 2018
Fujifilm Medical Systems USA Inc. announced a joint collaboration with Korean-based medical artificial intelligence (AI...
ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...
GE Healthcare Introduces Invenia ABUS 2.0
Technology | Ultrasound Women's Health | December 03, 2018
GE Healthcare recently launched the Invenia automated breast ultrasound (ABUS) 2.0 system in the United States. This...
Snoring Poses Greater Cardiac Risk to Women
News | Women's Health | November 29, 2018
Obstructive sleep apnea (OSA) and snoring may lead to earlier impairment of cardiac function in women than in men,...
ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution
Technology | Computer-Aided Detection Software | November 28, 2018
November 28, 2018 — ScreenPoint Medical announced it has received 510(k) clearance from the U.S.
Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

News | Contrast Media | November 27, 2018
Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in...